Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: don roberson who wrote (2572)	1/12/1998 5:21:00 PM
From: Afaq Sarwar	Read Replies (2) \| Respond to of 3906

Don, I would assume that it covers both the drug and the delivery system. Without the delivery system what would be the point. But instead of assuming this, I'll call the company and ask them. Hopefully they will be able to clarify this. Over on the VVUS thread some one had posted that VVUS has filed a counter action against HVSF regrding the patent issue. I asked them to substantiate this. But so far no one has been able to do that. So most likely it was a rumor that the over zealous VVUS posters wanted to spread to give confidence to the VVUS shareholders on the patent issue. With a hot selling product, $100 mil. in revenues, and about $100 mil. in cash, the VVUS stock is selling for a fraction of what it was few weeks ago. This may explain their need to dream up stories. On the other hand with every little new step that the new management is taking, I am becoming more and more confident about the long term future of HVSF and the standing of its patent position. Afaq Sarwar